SGLT-2 inhibitors were recently reported to be associated with euglycemic diabetic ketoacidosis; however, only a limited number of well-structured clinical trials have provided supportive evidence [43]. This evidence concerns the gene SLC5A2 and diabetic ketoacidosis.